Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.

Heier, Jeffrey S; Ho, Allen C; Boyer, David S; Csaky, Karl; Vitti, Robert; Perlee, Lorah; Chu, Karen W; Asmus, Friedrich; Leal, Sergio; Zeitz, Oliver; Cheng, Yenchieh; Schmelter, Thomas; Brown, David M

Heier, Jeffrey S; Ho, Allen C; Boyer, David S; Csaky, Karl; Vitti, Robert; Perlee, Lorah; Chu, Karen W; Asmus, Friedrich; Leal, Sergio; Zeitz, Oliver; Cheng, Yenchieh; Schmelter, Thomas; Brown, David M.

Afiliação

Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA.
Ho AC; Wills Eye Hospital, Philadelphia, PA, USA.
Boyer DS; Retina-Vitreous Associates Medical Group, Beverly Hills, CA, USA.
Csaky K; Retina Foundation of the Southwest, Dallas, TX, USA.
Vitti R; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Perlee L; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Chu KW; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Asmus F; Bayer AG, Berlin, Germany.
Leal S; Bayer Consumer Care AG, Basel, Switzerland.
Zeitz O; Bayer AG, Berlin, Germany.
Cheng Y; Department of Ophthalmology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Schmelter T; Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Brown DM; Bayer AG, Berlin, Germany.

J Vitreoretin Dis ; 7(1): 8-15, 2023.

Article em En | MEDLINE | ID: mdl-37008402

Palavras-chave

age-related macular degeneration; angiopoietin-2; investigational clinical trials; vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: J Vitreoretin Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google